health benefits provider, to include the majority of women diagnosed
with node-negative, estrogen receptor-positive breast cancer.
-- Established exclusive marketing agreement with GeneKor to distribute
Oncotype DX in Greece.
-- Expanded partnership with Teva Pharmaceutical Industries Ltd. to
include distribution of Oncotype DX in Turkey.
-- Studies presented at the American Society of Clinical Oncology's
Gastrointestinal Cancers Symposium in January identified genes that
could help predict the likelihood of recurrence and chemotherapy
benefit for early-stage (stage II and III) colon cancer.
-- Based on multiple clinical studies and analysis, reached a key
milestone with the finalization of an 18-gene panel for our Oncotype DX
colon cancer assay, which is now undergoing analytical validation. The
company anticipates beginning a clinical validation study of the assay
in the second half of 2008.
-- Announced plans to evaluate the use of the Oncotype DX 21-gene breast
cancer panel, and also seek to identify other genes that may be used
for treatment planning in women with ductal carcinoma in situ, or DCIS,
which affects approximately 60,000 women per year in the United States.
-- Under our collaboration with Pfizer, we received our first payments for
the initiation of research to develop a genomic test to estimate the
risk of recurrence following surgery for patients with stage I-III
renal carcinoma, clear cell type.
Conference Call Details
To access the live conference call today, May 6 at 4:30 p.m. Eastern
Time via phone, please dial (877) 356-8064 from the United States and
Canada or (706) 758-4314 internationally. The conference ID is 45418205.
Please dial in appr
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved